TY - JOUR
T1 - In vivo induction of IL-6 by administration of exogenous cytokines and detection of de novo serum levels of IL-6 in tumor-bearing mice
AU - McIntosh, J. K.
AU - Jablons, D. M.
AU - Mule, J. J.
AU - Nordan, R. P.
AU - Rudikoff, S.
AU - Lotze, M. T.
AU - Rosenberg, S. A.
PY - 1989/1/1
Y1 - 1989/1/1
N2 - We investigated the capacity of several recombinant cytokines to induce IL-6 in vivo in both normal and tumor-bearing (TB) mice. Intravenous administration of human rhTNF-α, rhIL-1, rhIL-2, rhIFN-α A/D, and rmIFN-γ were all capable of inducing circulating IL-6. TB animals consistently produced more IL-6 in response to rhTNF-α than did normal mice (2 h after 4 μg rhTNF-α, TB = 24,100 HGF U/ml, non-TB = 3600 HGF U/ml of IL-6). A single daily i.v. dose of rhTNF-α (4 μg/mouse/day) for 5 days led to decreased IL-6 induction in TB animals by day 3 of treatment (peak levels of IL-6, day 1 = 72,800 HGF U/ml, day 3 = 23,400 HGF U/ml, day 5 = 26,400 HGF U/ml). rhIL-1 administration also resulted in considerable IL-6 production, although peak values were less than those resulting from administration of rhTNF-α. Administration of rhIL-1 induced similar IL-6 levels (TB = 10,025 and non-TB = 10,600 HGF U/ml) in TB and normal mice. Single high doses of rhIL-2, rhIFN-α A/D, and rmIFN-γ induced lower but consistent levels of circulating IL-6 in mice with and without tumor. In addition, sera of untreated TB mice contained levels of IL-6 which paralleled the extent of tumor burden (serum IL-6 in day 30 MCA 106 TB mice = 420 HGF U/ml). The detection of de novo IL-6 was also confirmed in animals bearing tumors of different histologies (the MCA 102 sarcoma, MCA 38 adenocarcinoma, and B16 melanoma). At no time was IL-6 measurable in the sera of untreated normal mice. The identification of IL-6 was verified by neutralization studies using specific antimurine IL-6 antibody. Although the exact role of IL-6 in TB animals remains to be elucidated, its known pleotrophic immune and metabolic effects may be important in the host response to malignancy.
AB - We investigated the capacity of several recombinant cytokines to induce IL-6 in vivo in both normal and tumor-bearing (TB) mice. Intravenous administration of human rhTNF-α, rhIL-1, rhIL-2, rhIFN-α A/D, and rmIFN-γ were all capable of inducing circulating IL-6. TB animals consistently produced more IL-6 in response to rhTNF-α than did normal mice (2 h after 4 μg rhTNF-α, TB = 24,100 HGF U/ml, non-TB = 3600 HGF U/ml of IL-6). A single daily i.v. dose of rhTNF-α (4 μg/mouse/day) for 5 days led to decreased IL-6 induction in TB animals by day 3 of treatment (peak levels of IL-6, day 1 = 72,800 HGF U/ml, day 3 = 23,400 HGF U/ml, day 5 = 26,400 HGF U/ml). rhIL-1 administration also resulted in considerable IL-6 production, although peak values were less than those resulting from administration of rhTNF-α. Administration of rhIL-1 induced similar IL-6 levels (TB = 10,025 and non-TB = 10,600 HGF U/ml) in TB and normal mice. Single high doses of rhIL-2, rhIFN-α A/D, and rmIFN-γ induced lower but consistent levels of circulating IL-6 in mice with and without tumor. In addition, sera of untreated TB mice contained levels of IL-6 which paralleled the extent of tumor burden (serum IL-6 in day 30 MCA 106 TB mice = 420 HGF U/ml). The detection of de novo IL-6 was also confirmed in animals bearing tumors of different histologies (the MCA 102 sarcoma, MCA 38 adenocarcinoma, and B16 melanoma). At no time was IL-6 measurable in the sera of untreated normal mice. The identification of IL-6 was verified by neutralization studies using specific antimurine IL-6 antibody. Although the exact role of IL-6 in TB animals remains to be elucidated, its known pleotrophic immune and metabolic effects may be important in the host response to malignancy.
UR - http://www.scopus.com/inward/record.url?scp=0024317712&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024317712&partnerID=8YFLogxK
M3 - Article
C2 - 2499626
AN - SCOPUS:0024317712
SN - 0022-1767
VL - 143
SP - 162
EP - 167
JO - Journal of Immunology
JF - Journal of Immunology
IS - 1
ER -